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Abstract.  The biological activity of many cytokines is 
regulated by binding proteins present at the cell sur- 
face, in extracellular matrices or in soluble phase.  We 
describe here a  TGF-fl binding protein that is both an 
extracellular matrix and a cell surface protein.  When 
intact extracellular  matrices of HEP-G2 cells were 
affinity cross-linked with  ~25I-TGF-fll, two major bind- 
ing components were seen:  a 250-kD, proteoglycan- 
like molecule, presumed to be betaglycan, and a 
60-kD protein.  The 60-kD TGF-l~-binding protein was 
also present at the cell surface.  It could be released 
from the cell surface by treating cells with high salt, 
heparin,  chondroitin sulfate, heparitinase,  or chon- 
droitinase,  indicating that it is bound to heparan  sul- 
fate and chondroitin  sulfate proteoglycans.  The 60-kD 
protein bound TGF-/~I  with an apparent dissociation 
constant of 1.6 nM, and there were 30,000 binding 
sites per cell at the cell surface.  In addition to the 
HEP-G2 cells and another hepatoma cell line,  the 
60-kD protein was also found in a human colon carci- 
noma (HT-29) cell line but not in rat kidney (NRK- 
49F) or human fibroblast (HUT-12) cell lines.  The 
60-kD protein could be extracted from cells contain- 
ing it and transferred to the surface of previously 
negative cells. The 60-kD protein may serve to regu- 
late the binding of TGF-fl to its signal transducing 
receptors by targeting TGF-fl to appropriate locations 
in the microenvironment of cells. 
T  GF-/3'S play an important role in the regulation  of cell 
proliferation  and  in  tissue  repair  (for  reviews  see 
Roberts  and  Sporn,  1990;  Massagu6,  1990).  The 
TGF-/3 family consists of three known isoforms,  TGF-/31, 2, 
and 3, that are structurally and functionally  closely related 
to one another. 
TGF-/3 is a potent growth suppressor for epithelial,  my- 
eloid, and lymphoid cells. This together with the observation 
that many transformed cells are resistant to the growth sup- 
pressing effects of TGF-/3 suggests that TGF-/3 functions  as 
a  general  homeostatic  factor  suppressing  undesired  cell 
proliferation.  Consequently,  abnormalities  in TGF-/3 func- 
tion  have  been  implicated  in  cellular  transformation  and 
malignancy (Masui et al., 1986; Shipley et al., 1986; Knabbe 
et al.,  1987) and in a lymphoproliferative disorder seen in 
mice lacking a functioning  TGF-fll gene (Shull et al., 1992; 
Kulkarni  et al.,  1993).  A prominent feature among TGF-/~ 
activities is the ability of this growth factor to enhance the 
deposition of extracellular matrix and stabilize such matrices 
(Sporn et al.,  1983; Roberts et al.,  1986).  This is accom- 
plished by increased production of extracellular  matrix pro- 
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teins (Baiza et al.,  1988; Ignotz and Massagu6,  1986; Bas- 
sols and Massagu6,  1988;  Pearson et al.,  1988) and their 
cellular receptors (Ignotz  and Massagu6,  1987) as well as 
decreased proteolysis (Edwards  et al.,  1987; Laiho et al., 
1987). These activities  of TGF-/~ are likely to be important 
in tissue repair. 
TGF-fl  induces  its  own production  in  many  cells  (van 
Obberghen-Schilling  et al.,  1988; Kim et al.,  1989), and it 
has been hypothesized that sometimes this  self-amplifying 
cascade would lead to excessive and destructive fibrous tis- 
sue formation  (Border and Ruoslahti,  1992).  The fact that 
TGF-/~ is the driving force in many fibrotic disorders is sug- 
gested by elevated TGF-/~ expression at the site of excessive 
matrix formation and by the ability of neutralizing anti-TGF-~ 
antibodies  to  hinder  the development and progression of 
such disorders (Border and Ruoslahti,  1992).  Considering 
the potency of TGF-/3 in eliciting both beneficial and poten- 
tially harmful responses, an effective regulatory system bal- 
ancing  TGF-fl activity would seem to be a necessity. 
One of the regulators of TGF-fl activity is the binding  of 
TGF-fl to cell surface components other than  signal trans- 
ducing  receptors and to extracellular  matrices  (Ruoslahti 
and Yamaguchi, 1991). A cell surface proteoglycan, betagly- 
can (also known as TGF-~ receptor type HI), binds TGF-/3 
at the cell surface (Massagu6,  1992) apparently enhancing 
the binding of TGF-/3 to one of the signal transducing  recep- 
tors (Wang et al.,  1991). A number of extracellular  matrix 
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These include fibronectin (Fava and McClure, 1987), throm- 
bospondin (Murphy-UUrich  et al.,  1992), collagen type IV 
(Paralkar et al., 1991) and the core proteins of small intersti- 
tial proteoglycans of the decorin family (Yamaguchi et al., 
1990). The binding of TGF-/3 to the decorin-type proteogly- 
cans neutralizes  the activity of the growth factor (Yamaguchi 
et al., 1990; Border et al., 1992). While betaglycan and the 
decorin-type proteoglycans bind  TGF-/3 through  the core 
protein, TGF-/3 can also bind to glycosaminoglycan  chains 
of proteoglycans (McCaffrey et al.,  1992).  Immunohisto- 
chemical stainings  have shown that,  indeed, TGF-/3 can be 
found in the extracellular  matrix in vivo (Flanders  et al., 
1989; Heine et al.,  1990; Silberstein  et al.,  1992), but the 
binding proteins involved in this localization  are not known. 
In addition  to regulating  the receptor binding  of TGF-/3, 
cell surface and ECM binding proteins influence TGF-/3 ac- 
tivity by sequestering  the growth factor at the location of the 
binding  protein.  We have identified a 60-kD protein that in 
addition to binding TGF-/3 can bind to heparin/heparan  sul- 
fate and chondroitin  sulfate  proteoglycans and hence may 
target TGF-/3 to cell surfaces and ECMs. 
Materials and Methods 
Materials 
Hep-G2, Hep-3B, HT-29,  and NRK-49F cells were obtained from Ameri- 
can Type Culture Collection (HB 8065,  HB 8064,  HTB 38,  CRL  1570, 
respectively). HUT-12 cells were kindly provided by Dr. J. Leavitt (Leavitt 
et al., 1987).  FCS was purchased from Tissue Culture Biologicals (Tulare, 
CA) and L-glutamine and antibiotics from Irvine Scientific (Santa Ana, 
CA).  DME  was  from  GIBCO  BRL  ((3aithersburg,  MD),  carder-free 
Na125I from  Dupont-NEN  (Burbank,  CA),  IODO-GEN  and  disuccini- 
midyl suberate from Pierce (Rockford, IL). SDS-PAGE precast gels were 
from Novex (San  Diego,  CA).  Molecular weight standards came from 
GIBCO BRL and Centricon micro-concentrator from Amicon (Danvers, 
MA).  Vs protease (EC 3.4.21.19,  Staphylococcus aureus endoproteinase 
Glu-C) was from Boehringer Mannheim Corp. (Indianapolis, IN). Vydac 
218TP54  column (4.6  x  250 mm) was from Vydac  Separations Group 
(Hesperia, CA). All other chromatographic materials including pre-packed 
PD-10 columns were from Pharmacia (Uppsala, Sweden). Heparitinase I 
and chondroitinase ABC were from Seikagakn (Tokyo, Japan). Other chem- 
icals came from Sigma Immunochemicals (St. Louis, MO). 
Cell Cultures 
Cells were grown at 37°C in a humidified 10% C(h in air atmosphere in 
DME containing 10% FCS, l0 mM L-glutamine, 100 IU/mi penicillin and 
100/zg/ml streptomycin. Confluent cultures were detached by treatment for 
5 min with PBS containing 0.2 mg of EDTA and 0.5 rag of trypsin per ml 
and replated at least 18 h before the start of each experiment. 
TG  F-f31 
TGF-/31 was expressed in CHO cells and purified as described earlier (Gen- 
try et al.,  1987).  Before use,  the purity of each stock was verified by 
reversed-phase HPLC on a Vydac 218TP54  column. The sample was dis- 
solved in 0.06%  trifluoroacetic acid (TFA) and injected onto the column 
equilibrated with 0.06%  TFA.  A  linear gradient of acetonitrile (0-60%) 
containing 0.06%  TFA was used to elute the protein. Iodination of TGF-/31 
was done using Iodo-Gen according to the manufacturer's instructions. The 
specific activity of the label ranged from 80 to 150 ~Ci//~g. 
1.  Abbreviations  used  in  this paper:  ECM,  extracellular matrix;  TFA, 
trifluoroacetic acid. 
Ligand Binding and AJJinity  Labeling 
Confluent monolayers of cells were used for affinity labeling experiments. 
The  conditions used  were  essentially as  described earlier  (Massngu~, 
1987).  The following buffers were used: 25 mM Hepes, pH 7.4,  125 mM 
NaC1,  5 mM MgSO4, 5 mM KCI, 1 mM CaCI2,  2 mg/mi BSA ("binding 
buffer");  10  mM  Tris-HC1,  pH  7.4,  150  mM  NaCi,  1%  Triton X-100 
("solubilization buffer"); 10/zg/mi antipain, 10 #g/mi leupeptin, 2 mM ben- 
zamidine, I mM EDTA ("protease inhibitor cocktail,  ~ final concentrations). 
A fresh stock of disuccinimidyl suberate (DSS) (10 mg/ml in DMSO) was 
prepared for each experiment and a 1:200 dilution in binding buffer without 
BSA was used in cross-linking for 15 min on ice. The reaction was quenched 
by 10 mM Tris-HCl, pH 7.4,  150 mM NaCI and the samples were treated 
as indicated. 
Electrophoresis, Autoradiography, 
and Densitometric Scanning 
SDS-PAGE was performed according to Laemmli (1970). For autoradiogra- 
phy the gels were fixed after electrophoresis in 10% isopropanol, 10% ace- 
tic acid for 15 min and dried. Kodak X-O-MAT/AR film (Eastman Kodak 
Co., Rochester, NY) with a Dupont Cronex enhancing screen was used for 
autoradiography.  Densitometric scans of the autoradiograms  were per- 
formed on a laser densitometer (Ultroscan XL, LKB 222-020). 
Peptide Maps 
To obtain peptide maps of the 60-kD TGF/5 binding protein and the type 
I TGF/3 receptor (TGF-/31RI), a large petri dish of HEP-G2 cells was affinity 
labeled with 400 pM of 125I-TGF-/31. The 60-kD TGF-/51 binding protein 
was released by eluting the culture with 1 M NaCl in binding buffer contain- 
ing 200/~g/mi/5-1actogiobulin as a carder. The proteins in the eluate were 
precipitated with 10% TCA, acetone washed and solubilized to 8 M urea, 
TBS, pH 7.4. To obtain TGF-/IIRI  after the NaCI extraction, the cells were 
washed three times with ice cold binding buffer without BSA, scraped off 
and extracted with solubilization buffer. The NaCI and Triton X-100 extracts 
were separated on a 4-12 % SDS-PAGE gel under reducing conditions. Pro- 
teins labeled with 125I-TGF-/31 were electroeluted from gel segments with 
Centrilutor  (Amicon) using Centricon 30-kD  cutoff microconcentrators 
and 50%  Laemmli running buffer containing 0.025%  SDS. The proteins 
were precipitated with 10%  TCA and Vs protease digestion was done as 
described (Stone et al.,  1990).  After digestion the samples were analyzed 
on a  18%  gel  under  reducing conditions, fixed,  dried,  and  autoradio- 
graphed. 
AJ~inity Measurements 
Various concentrations of 125I-TGF-/31 alone (from  10 to 300 pM) or a 
fixed concentration of 12~I-TGF-/31 (300 pM) and various concentrations of 
unlabeled TGF-/31 (total TGF-/31 concentration from 1 nM to 100 nM) was 
added to  HEP-3B  cultures on 24-well  dishes.  After a  3-h incubation, 
washes, and cross-linking, the cultures were extracted with solubilization 
buffer supplemented with protease inhibitor cocktail, and the soluble mate- 
rial was analyzed by SDS-PAGE on a 4-20% gel under nonreducing condi- 
tions. The autoradiograph of the fixed and dried gel was scanned along each 
lane. Based on the known quantity of total counts loaded per lane and the 
relative intensity of individual bands in autoradiogram scans, the amount 
of bound and free ligand at various TGF-/31 concentrations was determined. 
Cross-linking efficiency was 20% and the apparent amount of bound ligand 
was multiplied by a factor of five to take this fact into account. The cross- 
linking efficiency  was assessed by determining the percentage of TGF-/3 that 
migrated as a dhner in SDS-PAGE under reducing conditions. The satura- 
tion curve and Scalchard analysis were done with the LIGAND-program 
(National Institutes of Health) using the data points obtained with TGF-~I 
concentrations from 300 pM to 100 nM. 
Treatment of Cells with Glycosaminoglycan-degrading 
Enzymes 
Hep-3B cells were washed three times with Ham FI2/DME (vol/vol 1:1, 
37°C) medium containing 0.2%  BSA. Heparitinase I and chondroitinase 
ABC were added to the cultures in the above buffer at a concentration of 
0.02 U/ml and incubated for 90 rain at 37°C. The cells were washed three 
times with binding buffer before affinity labeling. 
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binding  protein  and  TGF-/31RI. HEP-G2 
cells were affinity-labeled with 500 pM of 
t2~I-TGF-fll. The 60-kD TGF-/31 binding 
protein was eluted with 1 M NaCI and the 
cells  were  solubilized.  The samples  were 
separated  on  SDS-PAGE under  reducing 
conditions;  the  60-kD  protein  and  TGF- 
/31RI  were  electroeluted  from  the  gel, 
alkylated,  digested  with  V8 protease,  and 
the resulting fragments were separated  on 
SDS-PAGE with an 18%  gel.  Lane 1, 60- 
kD protein;  lane 2, TGF-/31RI. 
Figure 1. Identification of 60-kD TGF-31 binding protein. HEP-G2 
cells on 6-well dishes were afffinity-labeled  using 200 pM of 125I- 
TGF-B1. The cultures were incubated with 0.5 ml buffer (binding 
buffer with 200 tzg/ml/~-lactoglobulin as a carrier) with or without 
1 M NaCI or 10/~g/ml heparin for 15 min. The proteins in the elu- 
ates  were  TCA-precipitated and  washed with  acetone.  The salt- 
extracted cultures were then further extracted with buffer contain- 
ing 1% Triton X-100, and the eluates and the Triton extracts were 
analyzed by SDS-PAGE followed by autoradiography (a). The Tri- 
ton X-100-insoluble material containing ECM proteins was solubi- 
lized with 8 M urea and 5 x  SDS-PAGE sample buffer and analyzed 
as above (b). 
Results 
Identification of the 60-kD Binding Protein as a 
Peripheral Membrane and ECM Protein 
Affinity labeling of cultured HEP-G2 cells with 125I-TGF-/3 
revealed three  apparent cell  surface-binding proteins  with 
relative sizes of 72, 95, and 280 kD in a Triton X-100 extract 
of the cell layer (Fig 1 a). The sizes of these components cor- 
respond to type I and II receptors of TGF-/3 and betaglycan, 
respectively. A surprising finding was that much of what ap- 
peared to be the TGF-/3-1abeled 72-kD complex, presum- 
ably corresponding to the type I receptor, could be released 
from the cells and the matrix by treating the cultures with 
high salt and heparin after the affinity labeling. These results 
suggested that the 72-kD band may consist of two compo- 
nents: type I receptor (TGF-/~LI), which remains bound to 
the cell layer upon the heparin and salt treatments, and an- 
other TGF-~ binding protein that is released by these treat- 
ments.  Subtracting  the  molecular  weight  of  the  TGF-/3 
subunit from the 72-kD size of the band indicates that the 
salt-released protein has a  molecular mass of 60 kD.  The 
Triton-insoluble material, consisting mainly of ECM,  was 
Figure 2. Presence of 60-kD TGF-/31 binding protein in some but 
not all cell lines. HUT-12, NRK-49F, HEP-3B, and HT-29 cells on 
6-well dishes were treated as described above. Buffer control, lanes 
1 and 2;  1 M NaCI treatment,  lanes 3 and 4; heparin treatment, 
lanes 5 and 6. Cell extracts, lanes 1, 3, and 5; eluates, lanes 2, 4, 
and 6. 
solubilized  with urea/SDS  and  also  analyzed.  The results 
show that the  72-kD complex and a  proteoglycan slightly 
smaller than betaglycan were present in this material (Fig. 
1 b).  The proteoglycan component could either be a  trun- 
cated  form of betaglycan or another  TGF-/3-binding pro- 
teoglycan,  biglycan,  which  in  SDS-PAGE migrates  above 
200  kD  (Fisher et al.,  1987).  Analysis of other cell lines 
showed that the 72-kD complex was also present in heparin 
and salt extracts of affinity-labeled HEP-3B and HT-29 hu- 
man colon carcinoma cells,  but the  HUT-12 human fibro- 
blasts and NRK-49F rat kidney cells, judging from the ab- 
sence  of  salt-extractable  72-kD  complex,  did  not  have 
detectable amounts of 60-kD protein (Fig.  2). 
TGF-#  IRI and 60-kD Binding Protein 
Are Distinct Proteins 
Affinity labeled 60-kD binding protein and TGF-~IRI were 
analyzed by proteolytic cleavage to examine whether they are 
structurally related. While two fragments from both proteins 
appeared to migrate similarly, both proteins also yielded sev- 
eral fragments that were not present in the digest of the other 
protein (Fig. 3), indicating that the 60-kD protein and TGF- 
~RI are two different proteins. 
Release of 60-kD TGF-~  I Binding Protein from the 
Cell Surface at Various NaCI Concentrations 
When a  stepwise gradient of NaC1 was used to elute  125I- 
TGF-/Yl/60-kD binding protein complex from HEP-3B cul- 
tures after affinity labeling, little dissociation was observed 
with  NaC1  concentrations  up  to  0.20  M  (Fig.  4).  Half- 
maximal and maximal elutions were obtained by NaC1 con- 
centrations of 0.33 and 0.50 M, respectively. There was an 
inverse relationship between the amount of 125I-TGF-/~l/60- 
kD protein in the NaCl-eluate and the amount detected in the 
Triton X-100 extracts of the NaCl-treated cell layer. A 72-kD 
band was also observed in the Triton X-100 residue solubi- 
lized with urea/SDS (not shown). In cultures not treated with 
NaCI before the Triton extraction,  the relative intensity ot 
the 72-kD band present in the urea/SDS fraction represent- 
ing extracellular matrix proteins was about half of that found 
in the Triton extract, indicating that a significant amount ot 
the 72-kD complex was bound to the matrix. 
AJ~nity of the 60-kD Binding Protein for mI-TGF-[31 
To determine the affinity of the 60-kD protein for TGF-/5'I, 
HEP-3B cells were incubated in the presence of various con- 
centrations of TGF-/31, and the quantity of free TGF-/31 and 
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cells by increasing concentrations of NaC1. HEP-3B cells on 6-well 
dishes were affinity labeled  with 500 pM of 125I-TGF-BI. The cell 
layers were eluted with increasing  concentrations of NaCI, and the 
eluates and cells were processed as described in the legend to Fig. 
1. Aliquots from NaCI and Triton extracts were separated by 4-12 % 
SDS-PAGE under reducing conditions (a). The autoradiograms of 
the fixed and dried gels were scanned to quantitate  the amount of 
the labeled 60-kD protein (b). The exposure time of the autoradio- 
grams was 24 h for the NaCI eluates and 3 d for the Triton X-100 
extracts.  In the graph, each absorbance from the NaCI eluates was 
multiplied  by three to adjust  for the difference  in exposure times. 
(o) NaC1; (o) Triton. 
that  bound  to  the  60-kD  component  was  determined.  In 
Scatchard analysis of  the data the six highest data points were 
used to minimize the interference of the binding of TGF-/5 
to the small amount of TGF-B1RI that comigrated with the 
TGF-/$ labeled 60-kD protein. As shown in Fig. 5, the bind- 
ing of TGF-/5'I to the 60-kD protein in these cells was satura- 
ble, and Scatchard analysis gave a rectilinear plot indicating 
a  single  class  of binding  sites  with  a  Kd of 1.6  nM.  The 
number of binding sites was 30,000 per cell. 
The 60-kD Protein Binds to Glycosaminoglycans 
The release of the 60-kD protein from the cell layers by high 
salt treatments suggested that the 60-kD protein may bind to 
glycosaminoglycan moieties on the cell  surface and in the 
ECM.  To study this question we treated HEP-3B cells with 
heparitinase or chondroitinase to eliminate potential binding 
sites for the 60-kD protein or with heparin and chondroitin 
sulfate  as  competitors  for those  sites.  Subsequent  affinity 
labeling with  TGF-/~ showed that each of these treatments 
reduced  the  labeling  of the  60-kD  component  (Fig.  6). 
Heparitinase  was  more  effective  than  chondroitinase  and 
heparin was more effective than chondroitin sulfate in reduc- 
ing the amount of 60-kD protein detected on the cell surface. 
Origin of 60-kD TGF-~  Binding Protein 
To determine whether the 60-kD protein originated from the 
cells or the serum present in the culture medium,  HEP-3B 
cell cultures were incubated in the presence or absence of  cy- 
cloheximide and/or  10%  FCS.  Addition of serum into the 
Figure 5.  Affinity of 60-kD protein for TGF-31.  HEP-3B cells  in 
duplicate wells of  24-well dishes were incubated for 3 h at 4°C with 
various  concentrations of 125I-TGF-B1 (from  10 to  300  pM)  or 
with a  fixed concentration of 125I-TGF-B1 (300 pM) and various 
concentrations of unlabeled  TGF-B1 (total  TGF-B1 from 1 to 100 
nM).  After cross-linking,  the cells  were solubilized  and extracts 
were analyzed by 4-20 % SDS-PAGE under nonreducing conditions 
(a).  The gel bands were quantitated  by scanning  and the results 
plotted in b. The inset shows a Scatchard  plot generated from the 
results. 
cultures  decreased  the  72-kD  labeling  to  '~50%  relative 
to the  serum-free  control  (Fig.  7).  Cycloheximide caused 
greatly  diminished  labeling  of  the  72-kD  band  both  in 
serum-free  and  serum-containing  cultures.  Taken together 
these results strongly suggest that the 60-kD binding protein 
does not originate from the serum but is synthesized by the 
cells and has a relatively short half-life on the cell surface. 
Transfer of the 60-kD Protein from Producer 
to Nonproducer Cells 
We next examined whether it would be possible to extract the 
60-kD binding component from 60-kD positive cells (HEP- 
3B) cells and transfer it to 60-kD negative (HUT-12) cells. 
Figure  6.  Binding  of 60-kD 
protein to glycosaminoglycans 
z0 
~.  were  digested  with  hepariti- 
,  nase  (ITase) or  chondroiti- 
O 
nase  ABC  (C'ase)  as  de- 
_  1.0  scribed  in  Materials  and 
Methods  or  pretreated  with 
heparin  (liP; 100  #g/ml)  or 
®  0.0.  .~,:~.o-~  ....  ~.  chondroitin  sulfate  A  (CSA; 
ttl  I} 
"~  b  o  times with the binding buffer 
~_  z  ~  ~  ~  100 #g/ml) and washed  three 
'outing"  '  before affini  W labeling  of the 
labeling  Pretreatment  cells  with  200  pM  of  1251- 
TGF-B1. Affinity labeling was 
done also in the presence of 100 #g/ml of heparin or chondroitin 
sulfate A. The relative intensity of 125I-TGF-Bl-labeled  60-kD pro- 
tein was quantified  by scanning after SDS-PAGE and autoradiog- 
raphy. 
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Figure 7. Effect of serum and cyclohexi- 
mide on 60-kD  protein labeling at the 
cell  surface.  HEP-3B cells  on  6-well 
dishes were incubated for 18 h  in the 
presence or absence of 10% FCS and/or 
20  mM  cycloheximide before  affinity 
labeling with 500 pM of 125I-TGF-3-1. 
The cells were detached, solubilized and 
analyzed by SDS-PAGE  on a 4-20% gel 
under reducing conditions. The relative 
intensity of  the 72-kD band representing 
the 60-kD protein-TGF-3 complex was 
quantitated by scanning (these cells have 
almost  no  detectable  TGF-/31RI; see 
Fig. 2). The bars represent mean of du- 
plicate experiments. 
Treatment of HEP-3B cultures with salt produced an extract 
that when incubated with HUT-12 cells rendered these cells 
positive for the 72-kD, heparin-elutable component (Fig. 8). 
An  eluate  from  the  HUT-12  cells  themselves,  when  in- 
cubated with HUT-12 cells, did not result in the labeling of 
a 72-kD heparin-elutable band.  An additional cross-linked 
complex of 30 kD was present both in Hep-3B and HUT-12 
eluates; the identity of this component is not known. 
Discussion 
We show here that one of the cell surface proteins that af- 
finity cross-link to radioactive TGF-/~ is a 60-kD peripheral 
membrane protein, and that this protein is bound to cell sur- 
faces  and  ECMs  through  an  interaction with  the  glycos- 
aminoglycan component of proteoglycans. Since the 60-kD 
protein has a high affinity for both TGF-# and glycosamino- 
glycans, its likely function is to modulate the availability of 
TGF-g/to cells by binding TGF-3 to cell surfaces and to the 
ECM. 
Figure  8.  Transfer of 60-kD 
TGF-B1 binding protein from 
cells  producing  it  to  non- 
producer  cells.  High salt ex- 
tracts  were  prepared  from 
confluent monolayer cultures 
of HEP-3B  (60-kD  protein- 
positive)  and  HUT-12 cells 
(60-kD protein-negative)  grown 
on 140-mm petri dishes by in- 
cubating the  cell layers with 
0.5 M NaCI in DMF contain- 
ing 1% FCS for 10 min. The 
extracts were diluted with 25 
mM Hepes, pH 7.4, contain- 
ing  10%  FCS  to give phys- 
iological salt concentration and added, along with control media, 
to HUT-12 cells  on 6-well dishes  for 4  h  at 37°C. After three 
washes, the cultures were afffinity-labeled  using 300 pM of t25I- 
TGF-/~I. The cultures were eluted with heparin (10 #g/ml),  and 
treated and analyzed by SDS-PAGE as described in the legend of 
Fig. 1. The cells analyzed in the lanes labeled HUT-12 received the 
high salt extract from HUT-12 cells, and the lanes labeled HEP 3B 
received the extract from HEP-3B cells. Control indicates the cells 
treated with media only. 
Our 60-kD protein is similar to the TGF-/~ receptors in 
that it binds TGF-/3 specifically and with high affinity, but it 
has the novel property that it can be released from the cells 
by treatments that reverse protein-glycosaminoglycan inter- 
actions. The specificity of the labeling of the 60-kD protein 
with TGF-B is evident from the fact that the 60-kD protein 
is one of the few cell surface proteins that become affinity- 
labeled  with  TGF-B.  Moreover,  like  the  labeling  of the 
known  receptors,  the  labeling  of the 60-kD  protein with 
~25I-TGF-31 was inhibited by unlabeled TGF-31. The affinity 
constant of  the 60-kD protein for TGF-31 was 1.6 nM, which 
is similar to the affinity measured for the type HI receptor, 
betaglycan (1.9 nM; Andres et al.,  1989). 
The  60-kD  protein  migrates  as  a  72-kD  protein  after 
affinity labeling with TGF-B. We have not yet been able to 
identify the protein without association with radiolabeled 
TGF-g/and the designation of 60 kD as its molecular mass 
is based on the assumption that one 12-kD subunit of TGF-B 
remains associated with it when the affinity-labeled products 
are analyzed by gel electrophoresis under reducing condi- 
tions.  The designation of our protein as  a  60-kD protein 
must, therefore, be considered tentative. 
The TGF-B-labeled 60-kD protein essentially comigrates 
with the type I TGF-B receptor at 72 kD. However, it can be 
distinguished from the type I receptor, because the receptor 
behaves  as  a  transmembrane  protein  (Massagu6,  1985), 
whereas the 60-kD protein can be released from the cell sur- 
face by treatments that  do not cleave polypeptide chains. 
Moreover, the peptide maps of the two proteins were differ- 
ent.  The comigration of the 60-kD protein with the type I 
receptor under the affinity-labeling conditions customarily 
used in the analysis of TGF-B-binding, cell-surface proteins 
explains why the 60-kD protein has  been generally over- 
looked. 
The 60-kD protein is not likely to be one of the other well- 
characterized TGF-B binding proteins. The proteins known 
to bind to TGF-B-fibronectin (Fava and McClure,  1987), 
thrombospondin (Murphy-Ullrich et al., 1992), type IV col- 
lagen  (Paralkar  et al.,  1991),  decorin (Yamaguchi  et al., 
1990),  betaglycan (Andres et al.,  1989),  type II receptor 
(Lin et al.,  1992),  c~2-macroglobulin  (O'Connor-McCourt 
and Wakefield, 1987), TGF-~ latency peptide (Miller et al., 
1992), endoglin (Cheifetz et al., 1992), and the amyloid pro- 
tein (Bodmer et al.,  1990)-each have a size different from 
that of the 60-kD binding protein described here. However, 
a protein in a rat pituitary cell line (GH3) that binds TGF-B 
and activin and has a molecular mass of 64 kD (Cheifetz et 
al.,  1988) is a candidate for being the same protein as our 
60-kD protein. The possible relationship of this 64-kD pro- 
tein, also termed type IV receptor, with the 60-kD protein 
described here remains to be clarified. 
Another protein that may have a relationship to our 60-kD 
protein is  follistatin (Vale  et al.,  1990),  a  35-kD activin- 
binding  protein that  inhibits  the binding  of activin to  its 
receptors. Follistatin is clearly not the same protein as the 
60-kD  protein,  because  follistatin  does  not  bind  TGF-B 
(Ling, N., personal communication) and the sizes of the two 
proteins (35 vs. 60 kD) also differ. It is also unlikely that fol- 
listatin and the 60-kD protein would be homologues, because 
follistatin is rich in cysteine and shows marked changes in 
mobility in SDS-PAGE upon reduction, whereas the 60-kD 
protein lacks this feature. However, what follistatin and the 
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cell-surface  glycosaminoglycans. Follistatin mediates  the 
binding of activin to cell surface proteoglycans (Nakamura 
et al., 1991), and we show here that the 60-kD protein can 
do  the  same  for  TGF-/$. Thus,  there  is  precedent  for 
glycosaminoglycan-binding proteins mediating ligand-cell 
surface receptor interactions. 
Several lines of evidence in this study show that the TGF- 
B-complexed 60-kD  protein is bound to cells through an 
interaction  with  the  glycosaminoglycan moieties  of pro- 
teoglycans. First, the binding of the 60-kD protein-TGF-/31 
complex to cell layers could be reversed by treating the cells 
with high salt or with heparin; both of these treatments dis- 
rupt protein-glycosaminoglycan interactions. Since TGF-/$ 
can interact directly with heparin (McCaffrey et al., t992), 
these  results  leave open  the possibility that the  complex 
would be binding to the cellular glycosaminoglycans  through 
its TGF-/3 component. However, our results indicate that the 
60-kD protein interacts directly with cellular glycosamino- 
glycans and heparin.  Thus,  treatment of cell layers with 
heparin  or  chondroitin  sulfate before  the  TGF-/~ affinity 
labeling reduced the  subsequent yield of the 60-kD  pro- 
tein-TGF-fl complex, indicating that the glycosaminoglycans 
had released the 60-kD protein from its binding to cell layer 
glycosaminoglycans. That the 60-kD protein labeling could 
also be reduced by treating cell layers with glycosamino- 
glycan-degrading enzymes points to the same conclusion. 
These results also indicate that the 60-kD protein can bind 
to both heparan sulfate and chondroitin sulfate proteogly- 
cans. Moreover, the weaker effect of chondroitin sulfate and 
chondroitinase suggested that, as is usual for protein-gly- 
cosaminoglycan interactions (Ruoslahti, 1988), chondroitin 
sulfate is a weaker binder of the 60-kD protein than heparan 
sulfate. Since TGF-~ itself binds only weakly to heparin, the 
main force of the binding of the 60-kD protein-TGF-~ com- 
plex to glycosaminoglycans  is likely to be contributed by the 
60-kD protein. However,  the complex may bind even more 
strongly than the 60-kD protein alone. 
The  glycosaminoglycan binding of the  60-kD  protein- 
TGF-/3 complex may direct the 60-kD protein and the TGF-/$ 
bound to it either to cell surfaces or to the ECM. We found 
that a substantial portion of the 60-kD protein-TGF-~ com- 
plex was bound to a detergent insoluble ECM fraction in the 
cell cultures. The distribution of  the complex in the detergent 
soluble (cell membrane) and insoluble (ECM) fractions was 
markedly different from that of betaglycan (Andres et al., 
1989), of which only a minor fraction was in the ECM com- 
partment. The 60-kD protein may, therefore, differ from the 
membrane protein  betaglycan in  that  the  60-kD  protein 
directs a higher portion of TGF-/$ bound to it to the ECM. 
This difference may be even more marked in tissues, which 
are likely to contain a more abundant ECM than the tumor 
cell cultures used in this study. 
The physiological significance of the 60-kD protein-TGF-/$ 
interaction we demonstrate here is unknown.  The 60-kD 
protein could serve as effectors in a negative feedback loop; 
increased TGF-B effect would lead to increased matrix for- 
marion,  including decorin (Bassols and Massagut,  1988; 
Border and Ruoslahti,  1992)  and the increased content of 
decorin along with the matrix-increased binding of the 60- 
kD protein would then sequester TGF-/3 to the matrix. This 
matrix could act as a buffer for TGF-/3 activity; it would com- 
pete with the receptors but would at the same time constitute 
a potential reservoir for prolonged TGF-/3 activity and coun- 
teract the extremely short plasma half-life (3-5 min) of ma- 
ture TGF-/~. These questions can now be studied with the 60- 
kD protein described here. 
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